Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Athersys finds new Japanese MultiStem partner in Healios

Executive Summary

Athersys Inc. announced public Japanese regenerative medicine company Healios KK as its new MultiStem cell therapy partner in Japan. This comes shortly after Athersys ended its March 2015 MultiStem alliance with Chugai Pharmaceutical, which returned all rights to Athersys in October 2015 after the candidate failed to achieve the primary or component secondary endpoints in Phase II for stroke.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • Manufacturing or Supply
    • R&D and Marketing (Licensing)

Related Companies